Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study to Assess the Safety, Antiviral Efficacy and Pharmacokinetics of PPI-461 in Patients With HCV Genotype-1 Infection

NCT01247194 is registered in ClinicalTrials.gov with Presidio Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01247194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01247194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study to Assess the Safety, Antiviral Efficacy and Pharmacokinetics of PPI-461 in Patients With HCV Genotype-1 Infection
Lead sponsor
Presidio Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2010
Completion date
June 30, 2011
Enrollment
24 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

chronic genotype 1 hepatitis c virus infection